Search research articles
Contact Us
Filters
Showing results (251-260 of 419) with videos related to
Page
of 42
Sort By:
BMJ Oncology
|
January 31, 2025
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
Matthew Tucker, Yu-Wei Chen, Martin H Voss, et al.
Journal of Natural Products
|
July 1, 2021
Feature-Based Molecular Networking for the Targeted Identification of G<sub>q</sub>-Inhibiting FR900359 Derivatives
Wiebke Hanke, Julian Patt, Judith Alenfelder, et al.
The Journal of Biological Chemistry
|
September 24, 2025
SAG1.3-derived Frizzled-targeting small-molecule compounds
Lukas Grätz, Ainoleena Turku, Pawel Kozielewicz, et al.
Scientific Reports
|
November 2, 2019
Author Correction: Varying levels of X chromosome coalescence in female somatic cells alters the balance of X-linked dosage compensation and is implicated in female-dominant systemic lupus erythematosus
Agnieszka I Laskowski, Daniel S Neems, Kyle Laster, et al.
Scientific Reports
|
May 31, 2019
Varying levels of X chromosome coalescence in female somatic cells alters the balance of X-linked dosage compensation and is implicated in female-dominant systemic lupus erythematosus
Agnieszka I Laskowski, Daniel S Neems, Kyle Laster, et al.
Clinical Genitourinary Cancer
|
May 1, 2019
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes
Yasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2018
PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial
Martin H Voss, David Chen, Albert Reising, et al.
World Journal of Urology
|
March 29, 2021
A qualitative framework of non-selection factors for cytoreductive nephrectomy
Andrew W Silagy, Kyrollis Attalla, Renzo G Dinatale, et al.
The Oncologist
|
April 8, 2015
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience
Richard M Bambury, David J Benjamin, Joshua L Chaim, et al.
JAMA Ophthalmology
|
September 2, 2021
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy
Jasmine H Francis, James J Harding, Alison M Schram, et al.
Page
of 42
Search research articles
Search
Showing results (251-260 of 419) with videos related to
Sort By:
Page
of 42
BMJ Oncology
|
January 31, 2025
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
Matthew Tucker, Yu-Wei Chen, Martin H Voss, et al.
Journal of Natural Products
|
July 1, 2021
Feature-Based Molecular Networking for the Targeted Identification of G<sub>q</sub>-Inhibiting FR900359 Derivatives
Wiebke Hanke, Julian Patt, Judith Alenfelder, et al.
The Journal of Biological Chemistry
|
September 24, 2025
SAG1.3-derived Frizzled-targeting small-molecule compounds
Lukas Grätz, Ainoleena Turku, Pawel Kozielewicz, et al.
Scientific Reports
|
November 2, 2019
Author Correction: Varying levels of X chromosome coalescence in female somatic cells alters the balance of X-linked dosage compensation and is implicated in female-dominant systemic lupus erythematosus
Agnieszka I Laskowski, Daniel S Neems, Kyle Laster, et al.
Scientific Reports
|
May 31, 2019
Varying levels of X chromosome coalescence in female somatic cells alters the balance of X-linked dosage compensation and is implicated in female-dominant systemic lupus erythematosus
Agnieszka I Laskowski, Daniel S Neems, Kyle Laster, et al.
Clinical Genitourinary Cancer
|
May 1, 2019
Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes
Yasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2018
PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial
Martin H Voss, David Chen, Albert Reising, et al.
World Journal of Urology
|
March 29, 2021
A qualitative framework of non-selection factors for cytoreductive nephrectomy
Andrew W Silagy, Kyrollis Attalla, Renzo G Dinatale, et al.
The Oncologist
|
April 8, 2015
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience
Richard M Bambury, David J Benjamin, Joshua L Chaim, et al.
JAMA Ophthalmology
|
September 2, 2021
Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy
Jasmine H Francis, James J Harding, Alison M Schram, et al.
Page
of 42